These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 16298037)

  • 21. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells.
    Zhou S; Turgeman G; Harris SE; Leitman DC; Komm BS; Bodine PV; Gazit D
    Mol Endocrinol; 2003 Jan; 17(1):56-66. PubMed ID: 12511606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene.
    Levy N; Tatomer D; Herber CB; Zhao X; Tang H; Sargeant T; Ball LJ; Summers J; Speed TP; Leitman DC
    Mol Endocrinol; 2008 Feb; 22(2):287-303. PubMed ID: 17962382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
    Nuttall ME; Stroup GB; Fisher PW; Nadeau DP; Gowen M; Suva LJ
    Am J Physiol Cell Physiol; 2000 Nov; 279(5):C1550-7. PubMed ID: 11029302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
    Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
    Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel function of the Fe65 neuronal adaptor in estrogen receptor action in breast cancer cells.
    Sun Y; Kasiappan R; Tang J; Webb PL; Quarni W; Zhang X; Bai W
    J Biol Chem; 2014 May; 289(18):12217-31. PubMed ID: 24619425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KISS1 is down-regulated by 17beta-estradiol in MDA-MB-231 cells through a nonclassical mechanism and loss of ribonucleic acid polymerase II binding at the proximal promoter.
    Huijbregts L; de Roux N
    Endocrinology; 2010 Aug; 151(8):3764-72. PubMed ID: 20534720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression.
    Applanat MP; Buteau-Lozano H; Herve MA; Corpet A
    Adv Exp Med Biol; 2008; 617():437-44. PubMed ID: 18497067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
    Liu Z; Shi HY; Nawaz Z; Zhang M
    Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
    Konduri SD; Medisetty R; Liu W; Kaipparettu BA; Srivastava P; Brauch H; Fritz P; Swetzig WM; Gardner AE; Khan SA; Das GM
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15081-6. PubMed ID: 20696891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
    Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
    Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells.
    Singleton DW; Feng Y; Chen Y; Busch SJ; Lee AV; Puga A; Khan SA
    Mol Cell Endocrinol; 2004 Jun; 221(1-2):47-55. PubMed ID: 15223131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
    Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
    Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.
    Secreto FJ; Monroe DG; Dutta S; Ingle JN; Spelsberg TC
    J Cell Biochem; 2007 Aug; 101(5):1125-47. PubMed ID: 17520659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
    Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
    Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ERalpha-positive MCF-7 breast cancer cells.
    Zhang Y; Zhou G; Wang H; Zhang X; Wei F; Cai Y; Yin D
    Oncology; 2006; 71(5-6):446-55. PubMed ID: 17878748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two estrogen response element sequences near the PCNA gene are not responsible for its estrogen-enhanced expression in MCF7 cells.
    Wang C; Yu J; Kallen CB
    PLoS One; 2008; 3(10):e3523. PubMed ID: 18949048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
    Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
    Webb P; Nguyen P; Kushner PJ
    J Biol Chem; 2003 Feb; 278(9):6912-20. PubMed ID: 12482846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways.
    Syed FA; Mödder UI; Fraser DG; Spelsberg TC; Rosen CJ; Krust A; Chambon P; Jameson JL; Khosla S
    J Bone Miner Res; 2005 Nov; 20(11):1992-2001. PubMed ID: 16234973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.